PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-21.98%
Both yoy net incomes decline, with TRVN at -2.10%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
22.78%
Some D&A expansion while TRVN is negative at -14.29%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
128.24%
SBC growth while TRVN is negative at -24.21%. John Neff would see competitor possibly controlling share issuance more tightly.
-92.68%
Negative yoy working capital usage while TRVN is 4.83%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
314.60%
A yoy AP increase while TRVN is negative at -225.86%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
26.98%
Some yoy usage while TRVN is negative at -109.03%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-101.99%
Negative yoy while TRVN is 829.22%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-120.47%
Negative yoy CFO while TRVN is 11.25%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
72.96%
CapEx growth of 72.96% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.96%
Investing outflow well above TRVN's 140.01%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
86.96%
Debt repayment growth of 86.96% while TRVN is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-90.54%
Negative yoy issuance while TRVN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.